scholarly journals Intracerebroventricular Administration of Fibroblast Growth Factor Receptor Inhibitor Attenuates High‐Phosphate Diet‐Induced Exercise Pressor Reflex Overactivation in Rats

2019 ◽  
Vol 33 (S1) ◽  
Author(s):  
Han‐Kyul Kim ◽  
Masaki Mizuno ◽  
Gary A. Iwamoto ◽  
Rie Ishizawa ◽  
Jere H. Mitchell ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Intracerebroventricular Administration ◽  
Exercise Pressor Reflex ◽  
Pressor Reflex ◽  
High Phosphate ◽  
Receptor Inhibitor

Fibroblast Growth Factor Receptor Inhibitor–Associated Multifocal Serous Retinal Detachments: A Case Report

2021 ◽  
pp. 247412642110136
Author(s):  
Diana H. Kim ◽  
Tian Xia ◽  
Peter Bracha ◽  
Brian L. VanderBeek
Keyword(s):  
Case Report ◽  
Growth Factor ◽  
Urothelial Carcinoma ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Metastatic Urothelial Carcinoma ◽  
Optical Coherence Tomography Imaging ◽  
Receptor Inhibitor

Purpose: This report aims to describe a case of bilateral, multifocal neurosensory retinal detachments that developed during erdafitinib therapy for metastatic urothelial carcinoma. Methods: A case report with color fundus imaging and spectral-domain optical coherence tomography imaging is presented. Results: A 50-year-old man with metastatic urothelial carcinoma had an unremarkable baseline ophthalmic examination prior to starting erdafitinib. At 3-month follow up, an examination revealed bilateral, multifocal retinal detachments. Because the patient was asymptomatic and erdafitinib was the only drug to which his tumor had responded, he was kept on the medication with close ophthalmic monitoring. Conclusions: Erdafitinib, a fibroblast growth factor receptor inhibitor, can cause bilateral, multifocal retinal detachments. Continuation of erdafitinib may be considered in patients without significant visual impairment when the overall benefit of the medication appears to outweigh the risks.

scholarly journals Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398

2017 ◽  
Vol 16 (4) ◽  
pp. 614-624 ◽  
Author(s):  
Jharna Datta ◽  
Senthilkumar Damodaran ◽  
Hannah Parks ◽  
Cristina Ocrainiciuc ◽  
Jharna Miya ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Acquired Resistance ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Akt Activation ◽  
Receptor Inhibitor

scholarly journals Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma

2019 ◽  
Vol 189 (10) ◽  
pp. 2090-2101 ◽  
Author(s):  
Chiara Raggi ◽  
Karim Fiaccadori ◽  
Mirella Pastore ◽  
Margherita Correnti ◽  
Benedetta Piombanti ◽  
...  
Keyword(s):  
Growth Factor ◽  
Antitumor Activity ◽  
Fibroblast Growth Factor ◽  
Intrahepatic Cholangiocarcinoma ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Receptor Inhibitor
Sign in / Sign up

Export Citation Format

Share Document